A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Condition: Moderate to Severe Ulcerative Colitis
MeSH terms: Colitis; Colitis, Ulcerative; Ulcer
Study type: Interventional
Phase: Phase 2

Summary: 
      This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to
      severe ulcerative colitis (UC).
    

Detailed description: 
      This is a multicenter, multicountry, randomized, double-blind, placebo-controlled phase II
      clinical trial to evaluate the efficacy and safety of CBP-307 in subjects with moderate to
      severe ulcerative colitis (UC). CBP-307 capsules are administered orally. This study includes
      stage 1 and stage 2.

      Study Stage 1 After screening, subjects entered the randomized, double-blind,
      placebo-controlled induction therapy for 12 weeks.

      Subjects were screened at 1 to 21 days prior to the baseline visit. The eligible subjects
      were enrolled and randomized at the baseline visit. As per study protocol (version 5.0 or
      earlier), subjects received CBP 307 0.1 mg, CBP-307 0.2 mg, and placebo at a ratio of 1:1:1.
      The subjects enrolled under protocol (version 6.0) were randomized to CBP-307 0.2 mg and
      placebo at a ratio of 1:1 into the 2 groups (approximately 52 subjects in each group) and
      stratified according to whether the subject failed a previous tumor necrosis factor (TNF)-α
      antagonist therapy. Subjects assigned were blinded to their treatment assignment (CBP-307 or
      placebo) in the 12-week double-blinded placebo-controlled treatment period.

      Subjects randomized to CBP-307 group underwent dose titration for 1 week, while those in
      placebo group underwent simulated titration. Both CBP-307 and placebo were administered
      through the oral route. For subjects in the CBP-307 0.1 mg QD group, a daily dose of 0.05 mg
      CBP-307 was given from Day 1 to Day 4; then a daily dose of 0.1 mg CBP-307 was given for 3
      days from Day 5 to Day 7; from Day 8, a daily target dose of 0.1 mg was administered. For
      subjects in the group of CBP-307 0.2 mg QD, a daily dose of 0.05 mg CBP-307 was given from
      Day 1 to Day 4; then, a dose of 0.1 mg CBP-307 was given daily for 3 days from Day 5 to Day
      7; from Day 8, a daily target dose of 0.2 mg was administered.

      For the subjects already enrolled as per study protocol version 5.0 or earlier, they
      continued the treatment in the Stage 1 according to the previous planned schedule.

      Eligible subjects completing 12 weeks of induction therapy in Stage 1 were permitted to enter
      Stage 2 to be evaluated for the long-term maintenance administration of CBP-307. Subjects who
      withdrew early from the study or completed the Stage 1, but did not enter Stage 2, entered a
      4-week safety follow-up period.

      Study stage 2 All subjects who completed 12 weeks of induction therapy in the study Stage 1
      and completed all examinations (including colonoscopy) at Week 12 (visit 11) could choose to
      enter the study Stage 2 of a total length of 40 weeks, including 36 weeks of continuous
      treatment and 4 weeks of safety follow up after the last dose. Subjects who chose to enter
      the Stage 2 signed an updated informed consent form (ICF) and screened for eligibility.

      The study Stage 2 contained sub-study 1 and sub-study 2. Subjects entered 1 of sub-studies
      based on their results of efficacy evaluation in the study Stage 1.

      Sub-study 1 (subjects who achieved clinical response by adapted Mayo score): Subjects who
      achieved clinical response at Week 12 in the study Stage 1 and met the eligibility criteria
      for Stage 2 entered sub study 1 of the study Stage 2 to receive double-blind maintenance
      treatment for 36 weeks (Week 13 to 48), i.e., the therapeutic regimen for them in Stage 1 was
      continually maintained. Safety follow-up was completed at 4 weeks after the last dose.
      Subjects who presented with recurrent UC during maintenance treatment were terminated from
      the treatment and withdrew from the study.

      For the subjects already enrolled as per study protocol version 5.0 or earlier, they followed
      the previous planned treatment in the sub-study 1 of Stage 2 study.

      Sub-study 2 (subjects who did not achieve clinical response by adapted Mayo score): Subjects
      who did not achieve clinical response at Week 12 in study Stage 1 and met the eligibility
      criteria for Stage 2 entered open-label treatment with CBP-307 0.2 mg. Subjects received
      CBP-307 QD at an oral dose of 0.2 mg in sub study 2 regardless of whether they received
      CBP-307 or placebo in the study Stage 1.

      For subjects who entered sub-study 2 of study Stage 2, 1-week dose titration was performed at
      Week 13. Dose titration involved administration of CBP 0.05 mg for 4 consecutive days from
      Titration Day 1 to Day 4, followed by administration of CBP-307 0.1 mg for 3 days from
      Titration Day 5 to Day 7, and administration of CBP-307 at a target dose of 0.2 mg initiated
      on Titration Day 8. After dose titration was completed, subjects received oral treatment with
      CBP-307 0.2 mg QD, for 36 weeks. Safety follow-up was completed at 4 weeks after the last
      dose. If the subjects did not achieve clinical response by the efficacy evaluation including
      colonoscopy at Week 24, the treatment was to be discontinued and the subjects were to
      withdraw from the study.
    

Intervention name(s): Double-Blind 0.2mg CBP-307; Double-Blind Placebo; Open-label CBP-307; Double-Blind 0.1mg CBP-307
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): 0.2 mg capsule oral administration; Placebo capsule oral administration; 0.2 mg capsule oral administration; 0.1 mg capsule oral administration
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment